Resources from the same session
234O - Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
Presenter: Michael Friedlander
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
235O - Efficacy and safety of Niraparib in Chinese Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose: A Subgroup Analysis of A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Presenter: Jianqing Zhu
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
236O - Olaparib (ola) plus bevacizumab (bev) as maintenance (mx) therapy in patients (pts) with newly diagnosed advanced ovarian carcinoma (OC): Japan subset of the PAOLA-1 trial
Presenter: Keiichi Fujiwara
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
237O - Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence for high-grade serous ovarian cancer patients with advanced disease
Presenter: Jing Li
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
238O - Deep learning magnetic resonance imaging radiomic predict platinum-sensitive in patients with epithelial ovarian cancer
Presenter: lei ruilin
Session: Proffered paper session on Gynaecological tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant abstracts 237O and 238O
Presenter: Fedro Peccatori
Session: Proffered paper session on Gynaecological tumours
Resources:
Slides
Webcast
LIVE Q&A
Presenter: Keiichi Fujiwara
Session: Proffered paper session on Gynaecological tumours
Resources:
Webcast
LIVE Q&A
Presenter: Keiichi Fujiwara
Session: Proffered paper session on Gynaecological tumours
Resources:
Webcast